Pharmafile Logo
Pharmafocus logo
Advanced Search

Antisoma

Showing 4 posts of 4 posts found.

Trial failures threaten UK biotech

February 18, 2011
Research and Development AML, AS1411, AS1413, Antisoma, Juvista, Renovo, UK biotech, acute myeloid leukaemia, anti-scarring, biotech

A number of late stage failures from British biotech firms have left a looming question mark over the future of …

News

Novartis drops late stage lung cancer candidate

November 11, 2010
Research and Development ASA404, Antisoma, NSCLC, Novartis, cancer research, lung cancer, non small cell lung cancer, non-small cell lung cancer

Novartis has discontinued phase III trials for its lung cancer candidate ASA404 after it once again failed to meet its …

News

Antisoma stages comeback with promising cancer drugs

May 20, 2010
Research and Development AML, Antisoma, chemotherapy, leukaemia

UK biotech Antisoma is looking to put previous late-stage trial failures behind it by focusing on two new cancer drugs. …

News

Antisoma cancer drug fails in phase III

March 29, 2010
Research and Development Antisoma, NSCLC, lung cancer

UK biotech Antisoma has suffered a disappointing late-stage failure with a potential lung cancer treatment it was developing with Novartis. …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025